» Articles » PMID: 20126975

TDGF1 is a Novel Predictive Marker for Metachronous Metastasis of Colorectal Cancer

Overview
Journal Int J Oncol
Specialty Oncology
Date 2010 Feb 4
PMID 20126975
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Teratocarcinoma-derived growth factor 1 (TDGF1) is a member of the epidermal growth factor-cripto FRL1 cryptic protein family and is involved in the activation of several different signaling pathways during embryonic development and cellular transformation. Previous reports show that TDGF1 regulates the activation of several signaling pathways and controls cellular transformation in embryonic status, whereas its significance in colorectal cancer (CRC) is not yet fully understood. The present study comprised 55 patients who underwent surgery for CRC, as well as two cell lines derived from human CRC. The correlation of gene expression with clinical parameters in patients was assessed. The biological significance of TDGF1 expression was evaluated by knockdown experiments in the cell lines. Seventeen of 55 (30.9%) cases exhibited a higher TDGF1 expression in cancerous regions than in marginal non-cancerous regions. Patients with high TDGF1 expression were statistically susceptible to a recurrence of the disease, and showed poorer disease-free survival than those with low expression. The assessment of TDGF1 knock-down in the 2 cell lines demonstrated that the siRNA inhibition resulted in a statistically significant reduction in cell growth and invasion. In conclusion, the present data strongly suggest the usefulness of TDGF1 as a predictive marker for metachronous metastasis in CRC patients.

Citing Articles

Competing endogenous RNAs regulatory crosstalk networks: The messages from the RNA world to signaling pathways directing cancer stem cell development.

Aria H, Azizi M, Nazem S, Mansoori B, Darbeheshti F, Niazmand A Heliyon. 2024; 10(15):e35208.

PMID: 39170516 PMC: 11337742. DOI: 10.1016/j.heliyon.2024.e35208.


Comparison of left- and right-sided colorectal cancer to explore prognostic signatures related to pyroptosis.

Luo S, Cai S, Zhao R, Xu L, Zhang X, Gong X Heliyon. 2024; 10(7):e28091.

PMID: 38571659 PMC: 10987941. DOI: 10.1016/j.heliyon.2024.e28091.


Exploring immune-related signatures for predicting immunotherapeutic responsiveness, prognosis, and diagnosis of patients with colon cancer.

Cao L, Ba Y, Yang J, Zhang H Aging (Albany NY). 2022; 14(12):5131-5152.

PMID: 35748788 PMC: 9271306. DOI: 10.18632/aging.204134.


Whence CRIPTO: The Reemergence of an Oncofetal Factor in 'Wounds' That Fail to Heal.

Freeman D, Rodrigues Sousa E, Karkampouna S, Zoni E, Gray P, Salomon D Int J Mol Sci. 2021; 22(18).

PMID: 34576327 PMC: 8472190. DOI: 10.3390/ijms221810164.


New Insights into Cancer Targeted Therapy: Nodal and Cripto-1 as Attractive Candidates.

Arboretto P, Cillo M, Leonardi A Int J Mol Sci. 2021; 22(15).

PMID: 34360603 PMC: 8345935. DOI: 10.3390/ijms22157838.